Episode 15 – In the Inquiry: The inner Experience of Leadership – Ross Youngs
Summary – Two months before his next round of federal funding, Ross Youngs got a call.
The program was shut down. No more money. Good luck.
He had 35 people on the project. He laid off 33 of them.
Then he called a PhD student whose research he was still funding and asked what he was missing.
“Ross, you have no idea what you don’t know.”
“I know that,” Ross told him. “Tell me what I wish I knew.”
That answer turned an algae-harvesting energy project into Biosortia, a drug discovery company.
Ross had already won once. Univenture made the Inc. 500 five years running, and he was named the SBA’s national Business Person of the Year in 1998. When he moved into biotech, several people told him not to even think about it.
“Had I been wise, I might have listened.”
That’s the conversation.
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline (October 8, 2026) by Nick Paul Taylor Zealand Pharma is paying Generate Biomedicines $30 million upfront to collaborate on multispecific drug candidates for metabolic diseases. Milestones could bring the total value of the deal above $1 billion. Obesity and other metabolic diseases form the backbone of Zealand’s pipeline,
Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines Deal between Swiss company, Defand Therapeutics could signal shift in global development (October 8, 2026) by Allison DeAngelis Roche is digging deeper into the biotech industry in China, striking a new partnership with a drug startup there. But rather than licensing the startup’s clinical-stage medicines, Roche is
Breaking Life Sciences (3 book series) October 1, 2026 | Ross Youngs The definitive trilogy that turns the invisible chemistry of life into measurable power, the right speed of innovation into a controllable system, and closed-loop biology into humanity’s next operating system. Most organizations are still flying blind. They pour billions into drug discovery while R&D productivity collapses under Eroom’s
